AstraZeneca PLC (NASDAQ:AZN) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ET
Company Participants
Pascal Soriot – Chief Executive Officer
Susan Galbraith – EVP, Oncology R&D
Thomas Powles – Professor of Genitourinary Oncology; Director, Barts Cancer Centre
Sunil Verma – SVP, Global Head, Oncology Franchise
Dave Fredrickson – EVP, Oncology Business
Matt Hellmann – VP, Early Oncology Development
Cristian Massacesi – Chief Medical Officer, Chief Development Officer Oncology
Melissa Scaltrisi – Head of Traditional Medicine
Leora Horn – Global Clinical Strategy Head for Lung
Conference Call Participants
Tony Ryan – Macquarie
Emily Field – Barclays
Christopher Uhde – SEB
Simon Baker – Redburn
Sam Fazeli – Bloomberg Intelligence
Alana Lelo – Guggenheim
Richard Parks – BNP Paribas Exane
Andrew Berens – Leerink Partners
Etzer Darout – BMO Capital Markets
Gonzalo Artiach – Danske Bank
Mattias Haggblom – Handelsbanken
James Gordon – JPMorgan
Luisa Hector – Berenberg
Rajan Sharma – Goldman Sachs
Operator
Welcome, ladies and gentlemen, to AstraZeneca’s Investor Conference Call ESMO 2024. Before I hand over to AstraZeneca’s management team, I’d like to read the safe harbor statement.
The Company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward looking statements with respect to the operation and financial performance of AstraZeneca.
Although we believe our expectations are based on reasonable assumptions, by their very nature, forward looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
Any forward-looking statements made on this call reflect the knowledge and information available at the time of this call. The Company undertakes no obligation to update forward looking statements.
Please also carefully review the
